Menu

Q Search

Prognosis

Thailand's Second Locally-Made Vaccine Set to Enter Human Trials

Bloomberg

By Randy Thanthong-Knight
February 18, 2021, 2:11 PM GMT+7

LISTEN TO ARTICLE

▶ 2:09

SHARE THIS ARTICLE











Thailand is set to begin human trials of a Covid-19 vaccine that deploys the same technology used by Moderna Inc. as the Southeast Asian nation pushes ahead with plans to develop its own shots against the coronavirus.

Bangkok-based Chulalongkorn University will begin clinical trials as early as April, making it Thailand's second inoculation program to enter clinical trials, according to Kiat Ruxrungtham, head researcher at the university's Center of Excellence in Vaccine Research and Development. The center is using new mRNA technology, and testing in transgenic mice showed the vaccine can prevent clinical symptoms and viremia after two shots, he said.

The university will enroll 72 participants in the first phase of human trials, while Phase 2 may involve between 300 to 600 participants. The two-dose vaccine will be administered three weeks apart and will be enlisted for a rolling review with the Thai drug regulator, Kiat said.

Thailand last week <u>announced</u> that the first locally developed vaccine will enter clinical trials in March as authorities seek to cut reliance on imports. The country is likely to kick off its vaccination drive after the arrival of the first lot of 2 million doses ordered from China's <u>Sinovac Biotech Ltd.</u> next week. The government has ordered an additional 61 million doses from AstraZeneca Plc. to inoculate 50% of its population by the end of the year.







Covid-19 Pushes Thailand's Vaccine Development to 'New Era'

Record; U.S. Cases Rising: Virus Update

U.S. City With 2.4 Million Population Has Just Six ICU **Beds Left**

Jokowi Orders Quick **Covid Response on** Indonesia's Outer Islands

Australian Delta **Outbreak Continues** as Vaccination Push Ramps Up

trials.

Even mough by the end of next year, we may have an oversupply of vaccine, we want to complete the vaccine development so that Thailand can be self-dependent for the next pandemic," Kiat said on Thursday.

If the trials are successful, Bangkok-based BioNet-Asia Co. can produce as many as 5 million doses of Chulalongkorn University's vaccine by the end of this year and 20 million doses annually from 2022, Kiat said. The developer expects Thailand to approve the vaccine for emergency use after the completion of the second phase of clinical

Have a confidential tip for our reporters? GET IN TOUCH

efore it's here, it's on the loomberg Terminal. LEARN MORE

The university has also started research on a second generation vaccine against the U.K. and South African variants of Covid-19 with a target to test it in mice in the next two months, Kiat said.

From The Web



ณ รีวา เจริญนคร คอนโดวิวแม่น้ำ ใกล้ สาทร เดินทางสะดวก เริ่ม 2.8 ล้าน

Na Reva Charoennakhon

อ่านเพิ่มเติม



ดูว่าค่าปลูกย้ายเซลล์รากผมใน บางบอน ราคาเท่าไร



Sponsored Links by Taboola

ขายรถอย่างไรให้ได้ราคาดี พร้อมวิธีกา รอัพราคารถของคุณ

Carsome Thailand



How To Remove Netflix Restrictions In Thailand... TheTopFiveVPN



Do You Speak English? Online ผมบาง หัวล้าน ดีขึ้นได้ง่ายๆ! แค่ไหนก็ Tutoring Jobs In The USA M... กลับมาดกดำได้...คลิกเลย! Online Tutor Jobs | Search Ads



TAAP | Keraden

อ่านเพิ่มเติม

The Era of Cheap Natural Gas Ends as Prices Surge by 1,000%

High Even as Vaccinations Rise

Wards Off Vaccine Hesitancy

In Rural Arkansas, a Shocking Loss

Wall Street's Hottest Commodity: College Grads With Excel Skills

Buffett Slows Buybacks, Sells Stocks With Market at Highs

Terms of Service Do Not Sell My Info (California) Trademarks Privacy Policy ©2021 Bloomberg L.P. All Rights Reserved

Careers Made in NYC Advertise Ad Choices Help